Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

  1. Levy, B.P.
  2. Giaccone, G.
  3. Besse, B.
  4. Felip, E.
  5. Garassino, M.C.
  6. Domine Gomez, M.
  7. Garrido, P.
  8. Piperdi, B.
  9. Ponce-Aix, S.
  10. Menezes, D.
  11. MacBeth, K.J.
  12. Risueño, A.
  13. Slepetis, R.
  14. Wu, X.
  15. Fandi, A.
  16. Paz-Ares, L.
Aldizkaria:
European Journal of Cancer

ISSN: 1879-0852 0959-8049

Argitalpen urtea: 2019

Alea: 108

Orrialdeak: 120-128

Mota: Artikulua

DOI: 10.1016/J.EJCA.2018.11.028 GOOGLE SCHOLAR